Document Detail

The effect of intraperitoneal 22-oxacalcitriol on secondary hyperparathyroidism in continuous ambulatory peritoneal dialysis patients (IPOX study).
MedLine Citation:
PMID:  14763068     Owner:  NLM     Status:  MEDLINE    
Secondary hyperparathyroidism is a major complication in uremic patients undergoing dialysis. Various active metabolites of vitamin D are used as oral treatment; however, in some patients, parathyroid hormone (PTH) is not ideally suppressed. Intravenous injection of an active form of vitamin D inhibits PTH more effectively than does oral administration. However, intravenous administration is often restricted by the complication of hypercalcemia. In the calcitriol analog 22-oxacalcitriol (OCT), the 22nd carbon atom is replaced by oxygen. The OCT analog has been reported to have a lesser hypercalcemic effect than does calcitriol. The present study was planned to determine whether intraperitoneal administration of OCT would be a more effective treatment of secondary hyperparathyroidism than intravenous administration is in CAPD patients who manage themselves at home. The results showed that OCT is stable in dialysis solution and that its intraperitoneal administration was effective for suppressing PTH in patients with secondary hyperparathyroidism.
Minoru Kubota; Yuki Iwanaga; Nozomi Ishiguro
Related Documents :
20951818 - 25-hydroxy vitamin d deficiency following pediatric hematopoietic stem cell transplant.
1816158 - Clinical, histological, and chemical characterization of ectopic calcification in dialy...
19191738 - Vitamin b12 deficiency is associated with coronary artery disease in an indian population.
20672448 - Tenofovir-linked hyperparathyroidism is independently associated with the presence of v...
12843148 - Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients:...
23155988 - Nutritional markers in patients undergoing chronic haemodialysis in jamaica.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Advances in peritoneal dialysis. Conference on Peritoneal Dialysis     Volume:  19     ISSN:  1197-8554     ISO Abbreviation:  Adv Perit Dial     Publication Date:  2003  
Date Detail:
Created Date:  2004-02-06     Completed Date:  2004-02-27     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9104803     Medline TA:  Adv Perit Dial     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  227-30     Citation Subset:  IM    
Oji Hospital, Kita-ku, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Calcitriol / administration & dosage*,  analogs & derivatives,  pharmacokinetics
Dialysis Solutions*
Hyperparathyroidism, Secondary / blood,  drug therapy*,  etiology
Injections, Intraperitoneal
Middle Aged
Parathyroid Hormone / blood
Peritoneal Dialysis, Continuous Ambulatory*
Reg. No./Substance:
0/Dialysis Solutions; 0/Parathyroid Hormone; 103909-75-7/maxacalcitol; 32222-06-3/Calcitriol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Differences in clinical and laboratory data of peritoneal dialysis patients selected according to bo...
Next Document:  Severe hyperparathyroidism despite paricalcitol therapy: one-year follow-up.